Claudia Sánchez-Marin

Claudia Sánchez-Marin

Auto-generated profile, based on publicly available information

Claudia Sánchez-Marin

Gastroenterology and Hepatology Department, Grupo de Investigación Clínica y Traslacional en Enfermedades Digestivas, Instituto de Investigación Marqués de Valdecilla, Santander, Spain

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2017 in United European Gastroenterology Journal
Verified
Journal Article
Open access
EDEnrique de-Madaria
Enrique de-Madaria
IHIván Herrera-Marante
Iván Herrera-Marante
VGVerónica González-Camacho
Verónica González-Camacho
LBLaia Bonjoch
Laia Bonjoch
NQNoé Quesada-Vázquez
Noé Quesada-Vázquez
DCDaniel Closa
Daniel Closa
Little is known regarding the optimal type of fluid resuscitation in acute pancreatitis (AP). The objective of this article was to compare the effect of lactated Ringer’s solution (LR) vs normal saline (NS) in the inflammatory response in AP. We conducted a triple-blind, randomized, controlled trial. Patients ≥ 18 admitted with AP were eligible. Patients were randomized to receive LR or NS. Primary outcome variables were number of systemic inflammatory response syndrome (SIRS) criteria at 24 hours, 48 hours and 72 hours and blood C-reactive protein (CRP) levels at 48 hours and 72 hours. In vitro complementary experiments were performed to further explore the interaction between pH, lactate and inflammation. Nineteen patients receiving LR and 21 receiving NS were analyzed. The median (p25–p75) number of SIRS criteria at 48 hours were 1 (1–2) for NS vs 1 (0–1) for LR, p = 0.060. CRP levels (mg/l) were as follows: at 48 hours NS 166 (78–281) vs LR 28 (3–124), p = 0.037; at 72 hours NS 217 (59–323) vs LR 25 (3–169), p = 0.043. In vitro, LR inhibited the induction of inflammatory phenotype of macrophages and NF-κB activation. This effect was not observed when using Ringer’s solution without lactate, suggesting a direct anti-inflammatory effect of lactate. Lactated Ringer’s is associated with an anti-inflammatory effect in patients with acute pancreatitis.

3 April 2020 in Gut
Verified
Journal Article
Closed access
PDF file
EDEnrique de-Madaria
Enrique de-Madaria
CSClaudia Sánchez-Marin
Claudia Sánchez-Marin
Irene Carrillo MurciaIrene Carrillo Murcia
Irene Carrillo Murcia
SVSanthi Swaroop Vege
Santhi Swaroop Vege
SCSerge Chooklin
Serge Chooklin
JMJosé J Mira
José J Mira
Objective This study aimed to develop and validate a patient-reported outcome measure (PROM) in acute pancreatitis (AP) as an endpoint centred on the patient. Design A PROM instrument (PAtieNt-rePoRted OutcoMe scale in acute pancreatItis, an international proSpEctive cohort study, PAN-PROMISE scale) was designed based on the opinion of patients, professionals and an expert panel. The scale was validated in an international multicentre prospective cohort study, describing the severity of AP and quality of life at 15 days after discharge as the main variables for validation. The COSMIN (COnsensus-based Standards for the selection of health status Measurement INstruments) methodology was applied. Both the design and validation stages considered the content and face validity of this new instrument; the metric properties of the different items, reliability (reproducibility and internal consistence), the construct, structural and criterion validity, responsiveness and interpretability of this scale. Results PAN-PROMISE consists of a seven-item scale based on the symptoms that cause the most discomfort and concern to patients with AP. The validation cohort involved 15 countries, 524 patients. The intensity of symptoms changed from higher values during the first 24 hours to lower values at discharge and 15 days thereafter. Items converged into a unidimensional ordinal scale with good fit indices. Internal consistency and split-half reliability at discharge were adequate. Reproducibility was confirmed using test–retest reliability and comparing the PAN-PROMISE score at discharge and 15 days after discharge. Evidence is also provided for the convergent-discriminant and empirical validity of the scale. Conclusion The PAN-PROMISE scale is a useful tool to be used as an endpoint in clinical trials, and to quantify patient well-being during the hospital admission and follow-up. Trial registration number NCT03650062

1 June 2017 in United European Gastroenterology Journal
Verified
Journal Article
Open access
VSVikesh K Singh
Vikesh K Singh
TGTimothy B Gardner
Timothy B Gardner
GPGeorgios I Papachristou
Georgios I Papachristou
MRMónica Rey‐Riveiro
Mónica Rey‐Riveiro
MFMahya Faghih
Mahya Faghih
EDEnrique de-Madaria
Enrique de-Madaria
Aims: Early aggressive fluid resuscitation in acute pancreatitis is frequently recommended but its benefits remain unproven. The aim of this study was to determine the outcomes associated with early fluid volume administration in the emergency room (FVER) in patients with acute pancreatitis.Methods: A four‐center retrospective cohort study of 1010 patients with acute pancreatitis was conducted. FVER was defined as any fluid administered from the time of arrival to the emergency room to 4 h after diagnosis of acute pancreatitis, and was divided into tertiles: nonaggressive (1000 ml).Results: Two hundred sixty‐nine (26.6%), 427 (42.3%), and 314 (31.1%) patients received nonaggressive, moderate, and aggressive FVER respectively. Compared with the nonaggressive fluid group, the moderate group was associated with lower rates of local complications in univariable analysis, and interventions, both in univariable and multivariable analysis (adjusted odds ratio (95% confidence interval): 0.37 (0.14–0.98)). The aggressive resuscitation group was associated with a significantly lower need for interventions, both in univariable and multivariable analysis (adjusted odds ratio 0.21 (0.05–0.84)). Increasing fluid administration categories were associated with decreasing hospital stay in univariable analysis.Conclusions: Early moderate to aggressive FVER was associated with lower need for invasive interventions.

2 January 2026 in Gut
Verified
Journal Article
Closed access
LGLucía Guilabert
Lucía Guilabert
KCKarina Cárdenas-Jaén
Karina Cárdenas-Jaén
AVAlicia Vaillo-Rocamora
Alicia Vaillo-Rocamora
MRMaría Lourdes Ruiz-Rebollo
María Lourdes Ruiz-Rebollo
FBFederico Bolado-Concejo
Federico Bolado-Concejo
EDEnrique de-Madaria
Enrique de-Madaria
Background: Recurrent acute pancreatitis (RAP) or acute-on-chronic flares in chronic pancreatitis (CP) have limited preventive options beyond addressing the underlying aetiology. Statins, due to their anti-inflammatory properties, have been proposed as a potential prophylactic treatment. Objective: We aimed to evaluate whether simvastatin could reduce the recurrence of pancreatitis. Design: At 23 centres, we conducted a triple-blind, randomised, controlled, superiority trial enrolling patients with at least two episodes of RAP or CP flares in the previous 12 months. Participants were randomly assigned to receive simvastatin or placebo for 1 year. The primary endpoint was the recurrence of pancreatitis. The target sample size was 144 patients; however, an interim analysis was planned in the event of slow recruitment. Results: A total of 85 patients (42.1% women) were included in the interim analysis. In the intention-to-treat analysis, no significant differences were observed regarding recurrence: 46.2% simvastatin versus 44.4% placebo; OR 1.07, 95% CI 0.43 to 2.66; p=0.88, or time to recurrence. No statistically significant differences were observed in recurrence in per-protocol analysis (35.5% simvastatin vs 41.9% placebo; OR 0.76, 95% CI 0.27 to 2.12; p=0.60). Development of diabetes mellitus was more frequent in the simvastatin group (4 vs 0 patients; OR not calculable, p=0.04). Conclusion: This trial, evaluating simvastatin versus placebo for the prevention of pancreatitis, did not demonstrate a reduction in recurrence rate, although results might be underpowered due to early termination. The relationship between statins in these patients and new-onset diabetes requires further investigation. Trial registration number: NCT04021498 .

5 June 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
Lucía GuilabertLucía Guilabert
Lucía Guilabert
KCKarina Cárdenas-Jaén
Karina Cárdenas-Jaén
JBJames L. Buxbaum
James L. Buxbaum
APAna García García de Paredes
Ana García García de Paredes
AVAlicia Vaillo-Rocamora
Alicia Vaillo-Rocamora
EDEnrique de-Madaria
Enrique de-Madaria
INTRODUCTION: The PAN-PROMISE symptom score is the first patient-reported outcome in acute pancreatitis (AP). It was developed and validated in a prospective cohort of patients to be used as an endpoint in research. The aim of this study was to assess the performance of the score in a large randomized controlled trial and its association with well-established AP endpoints. METHODS: This is an ancillary study of the WATERFALL trial, where PAN-PROMISE was evaluated at baseline, 24, 48, and 72 hours. The study examined the association between PAN-PROMISE with established endpoints in AP: severity, pancreatic and/or peripancreatic fat necrosis (necrosis), infected necrosis, intensive care unit admission, persistent organ failure, prolonged hospital stay, and mortality. Areas under the receiver operating characteristic curve were calculated and used to compare baseline PAN-PROMISE and baseline Bedside Index for Severity in AP (BISAP) for the prediction of these endpoints. RESULTS: In total, 248 patients from the WATERFALL trial were included. A statistically significant association was found between PAN-PROMISE and severity, necrosis, persistent organ failure, intensive care unit admission, and prolonged hospital stay at all checkpoints (P < 0.05). Higher scores were also significantly associated with infected pancreatic necrosis at 24, 48, and 72 hours and death at baseline and 24 hours. The PAN-PROMISE baseline score had slightly higher areas under the receiver operating characteristic curve than BISAP for severity and necrosis, but the results were not statistically significant. DISCUSSION: In the context of a randomized controlled trial, the PAN-PROMISE score, a patient-centered measure, has been validated with established AP outcomes and as an endpoint for future clinical trials.

1 June 2018 in Pancreatology
Verified
Journal Article
Closed access
CSClaudia Sánchez-Marin
Claudia Sánchez-Marin
SCSerge Chooklin
Serge Chooklin
VMVioleta Mauriz
Violeta Mauriz
RMRafael Mejuto
Rafael Mejuto
MRM. Lourdes Ruiz-Rebollo
M. Lourdes Ruiz-Rebollo
EDEnrique De-Madaria
Enrique De-Madaria